ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Community Cancer Center Defined

September 27, 1974

Greenberg: More Work Needs to be Done

November 7, 2014

NCI Charging Use Fee for Compounds In Repository

August 12, 1983

DCT Advisors OK 4 Contract Concepts In Therapeutics

June 28, 1991

Harkin, Specter Propose A $5.2-Billion Supplement For NIH. Senate Report Says NIH Funding At “Crisis Point.”

July 18, 2008

Trials Could Start Earlier If Model Contract Language Adopted, NCI and CEO Roundtable Say.

December 12, 2008